PKP-008 Long term stability of trastuzumab in serum samples

BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples unde...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2016-03, Vol.23 (Suppl 1), p.A181-A182
Hauptverfasser: García, J González, Nicolás, F Gutiérrez, Casariego, GJ Nazco, Romero, MM Viña, Díaz, R Ramos, de la Fuente, G, Sánchez, V Casañas, Martínez, M Llabres
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A182
container_issue Suppl 1
container_start_page A181
container_title European journal of hospital pharmacy. Science and practice
container_volume 23
creator García, J González
Nicolás, F Gutiérrez
Casariego, GJ Nazco
Romero, MM Viña
Díaz, R Ramos
de la Fuente, G
Sánchez, V Casañas
Martínez, M Llabres
description BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value
doi_str_mv 10.1136/ejhpharm-2016-000875.411
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552751958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552751958</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1008-247a8a61a803f7c01db2d72715876bfeb0e33cf3cfc25d41f772268116261e3b3</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EElXpO1hiTvHxPQMDqrhUVKIDzJadODRR0wQ7GcrEwovyJLgqMCId6Zzh-_8jfQhhIHMAJq98s-k3NrQZJSAzQohWYs4BTtCEEq6yPJf89O8W8hzNYqwdEYzpnLN8gq7Xj-sU1F8fn6tu94oHH1ocB-vqbT3scVfhIdg4jO9jax2udzj6MCbCtv3Wxwt0Vtlt9LOfPUUvd7fPi4ds9XS_XNysMgepO6NcWW0lWE1YpQoCpaOlogqEVtJV3hHPWFGlKagoOVRKUSo1gKQSPHNsii6PvX3o3kYfB9N0Y9ill4YKQZWAXOj_KFCaC5FrRRPFjpRrG9OHurVhb4CYg1DzK9QchJqjUJOEsm_652k_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784559872</pqid></control><display><type>article</type><title>PKP-008 Long term stability of trastuzumab in serum samples</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>García, J González ; Nicolás, F Gutiérrez ; Casariego, GJ Nazco ; Romero, MM Viña ; Díaz, R Ramos ; de la Fuente, G ; Sánchez, V Casañas ; Martínez, M Llabres</creator><creatorcontrib>García, J González ; Nicolás, F Gutiérrez ; Casariego, GJ Nazco ; Romero, MM Viña ; Díaz, R Ramos ; de la Fuente, G ; Sánchez, V Casañas ; Martínez, M Llabres</creatorcontrib><description>BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value &lt;0.05 was considered to be significant. The research protocol was approved by the local ethics committee of our institution.ResultsBlood samples from 4 patients a with diagnosis of HER2+ breast cancer receiving treatment with subcutaneus trastuzumab (Herceptin) were included in the study after providing written informed consent. We did not find a significant difference between the samples analysed immediately and those stored at -20°C for 60 days (p = 0.414) (table 1).Abstract PKP-008 Table 1PatientTrastuzumab concentration day 1 (μg/mL)Trastuzumab concentration day 60 (μg/mL)Difference (%)146484.327068-2.835050048682-4.65ConclusionIn our study, we observed that serum trastuzumab (Herceptin) samples stored at -20°C were stable for at least 2 months. This was consistent with previous studies.References and/or AcknowledgementsFicha Técnica HerceptinNo conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2016-000875.411</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Breast cancer</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A181-A182</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2016 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>García, J González</creatorcontrib><creatorcontrib>Nicolás, F Gutiérrez</creatorcontrib><creatorcontrib>Casariego, GJ Nazco</creatorcontrib><creatorcontrib>Romero, MM Viña</creatorcontrib><creatorcontrib>Díaz, R Ramos</creatorcontrib><creatorcontrib>de la Fuente, G</creatorcontrib><creatorcontrib>Sánchez, V Casañas</creatorcontrib><creatorcontrib>Martínez, M Llabres</creatorcontrib><title>PKP-008 Long term stability of trastuzumab in serum samples</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value &lt;0.05 was considered to be significant. The research protocol was approved by the local ethics committee of our institution.ResultsBlood samples from 4 patients a with diagnosis of HER2+ breast cancer receiving treatment with subcutaneus trastuzumab (Herceptin) were included in the study after providing written informed consent. We did not find a significant difference between the samples analysed immediately and those stored at -20°C for 60 days (p = 0.414) (table 1).Abstract PKP-008 Table 1PatientTrastuzumab concentration day 1 (μg/mL)Trastuzumab concentration day 60 (μg/mL)Difference (%)146484.327068-2.835050048682-4.65ConclusionIn our study, we observed that serum trastuzumab (Herceptin) samples stored at -20°C were stable for at least 2 months. This was consistent with previous studies.References and/or AcknowledgementsFicha Técnica HerceptinNo conflict of interest.</description><subject>Breast cancer</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kLtOwzAUhi0EElXpO1hiTvHxPQMDqrhUVKIDzJadODRR0wQ7GcrEwovyJLgqMCId6Zzh-_8jfQhhIHMAJq98s-k3NrQZJSAzQohWYs4BTtCEEq6yPJf89O8W8hzNYqwdEYzpnLN8gq7Xj-sU1F8fn6tu94oHH1ocB-vqbT3scVfhIdg4jO9jax2udzj6MCbCtv3Wxwt0Vtlt9LOfPUUvd7fPi4ds9XS_XNysMgepO6NcWW0lWE1YpQoCpaOlogqEVtJV3hHPWFGlKagoOVRKUSo1gKQSPHNsii6PvX3o3kYfB9N0Y9ill4YKQZWAXOj_KFCaC5FrRRPFjpRrG9OHurVhb4CYg1DzK9QchJqjUJOEsm_652k_</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>García, J González</creator><creator>Nicolás, F Gutiérrez</creator><creator>Casariego, GJ Nazco</creator><creator>Romero, MM Viña</creator><creator>Díaz, R Ramos</creator><creator>de la Fuente, G</creator><creator>Sánchez, V Casañas</creator><creator>Martínez, M Llabres</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201603</creationdate><title>PKP-008 Long term stability of trastuzumab in serum samples</title><author>García, J González ; Nicolás, F Gutiérrez ; Casariego, GJ Nazco ; Romero, MM Viña ; Díaz, R Ramos ; de la Fuente, G ; Sánchez, V Casañas ; Martínez, M Llabres</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1008-247a8a61a803f7c01db2d72715876bfeb0e33cf3cfc25d41f772268116261e3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Breast cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García, J González</creatorcontrib><creatorcontrib>Nicolás, F Gutiérrez</creatorcontrib><creatorcontrib>Casariego, GJ Nazco</creatorcontrib><creatorcontrib>Romero, MM Viña</creatorcontrib><creatorcontrib>Díaz, R Ramos</creatorcontrib><creatorcontrib>de la Fuente, G</creatorcontrib><creatorcontrib>Sánchez, V Casañas</creatorcontrib><creatorcontrib>Martínez, M Llabres</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García, J González</au><au>Nicolás, F Gutiérrez</au><au>Casariego, GJ Nazco</au><au>Romero, MM Viña</au><au>Díaz, R Ramos</au><au>de la Fuente, G</au><au>Sánchez, V Casañas</au><au>Martínez, M Llabres</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PKP-008 Long term stability of trastuzumab in serum samples</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2016-03</date><risdate>2016</risdate><volume>23</volume><issue>Suppl 1</issue><spage>A181</spage><epage>A182</epage><pages>A181-A182</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value &lt;0.05 was considered to be significant. The research protocol was approved by the local ethics committee of our institution.ResultsBlood samples from 4 patients a with diagnosis of HER2+ breast cancer receiving treatment with subcutaneus trastuzumab (Herceptin) were included in the study after providing written informed consent. We did not find a significant difference between the samples analysed immediately and those stored at -20°C for 60 days (p = 0.414) (table 1).Abstract PKP-008 Table 1PatientTrastuzumab concentration day 1 (μg/mL)Trastuzumab concentration day 60 (μg/mL)Difference (%)146484.327068-2.835050048682-4.65ConclusionIn our study, we observed that serum trastuzumab (Herceptin) samples stored at -20°C were stable for at least 2 months. This was consistent with previous studies.References and/or AcknowledgementsFicha Técnica HerceptinNo conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2016-000875.411</doi></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A181-A182
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2552751958
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Breast cancer
title PKP-008 Long term stability of trastuzumab in serum samples
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T20%3A46%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PKP-008%E2%80%85Long%20term%20stability%20of%20trastuzumab%20in%20serum%20samples&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Garc%C3%ADa,%20J%20Gonz%C3%A1lez&rft.date=2016-03&rft.volume=23&rft.issue=Suppl%201&rft.spage=A181&rft.epage=A182&rft.pages=A181-A182&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2016-000875.411&rft_dat=%3Cproquest_bmj_p%3E2552751958%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1784559872&rft_id=info:pmid/&rfr_iscdi=true